Shanghai Pharmaceuticals Holding Co., Ltd. (“SPH”) is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail.
In 2023, SPH reported revenues of US$36.9bn, and it ranked 438th on the 2023 Global Fortune 500 list, making the company one of the country’s major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of the SSE 180, CSI 300 index and MSCI.
